ClinicalTrials.gg
CompletedNCT06497517Updated Feb 7, 2025

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

A Phase 1 interventional study of GSK5464714- Camlipixant in Cough, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.

Enrollment
9th of 10
14 · median 44
Started
2024
with 1 other
Phase 1
7 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
8 of 10
Bellus Health Inc. - a GSK company

Among the 10 studies testing BLU-5937 in Cough, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 8th registered.

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About BLU-5937

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing BLU-5937 in Cough, or all of them as a file.
02

Study summary

This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.

03

Conditions studied

  • Cough

Browse trials for

Keywords

  • Camlipixant
  • GSK5464714-camlipixant
  • Healthy Participants
  • Pharmacokinetics
  • Cross-over Study
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, clinical laboratory tests, vital sign measurements, and 12-lead ECGs including the following:

    • Seated blood pressure (after 5 mins), average of 3 readings, is greater than or equal to (>=) 90/55 millimetre of mercury (mmHg) and less than or equal (\<=)140/90 mmHg at the screening visit.
    • Seated heart rate, average of 3 readings, is >= 40 beats per minutes (bpm) and \<= 99 bpm at the screening visit.
    • interval using the Fridericia formula (QTcF) on , average of 3 readings, is \<= 450 millisecond (msec) and 12-lead ECG findings considered normal or not by the investigator or designee at the screening visit.
  • Aspartate transferase (), Alanine transaminase (ALT), direct , indirect bilirubin, and total bilirubin within normal ranges at the screening visit and check-in. Only abnormal values up to 1.5 x may be repeated once
  • Continuous non-smoker who has never used nicotine- or tobacco-containing products or light smoker for the last 6 months prior to study screening
  • Body weight ≥ 50.0 kilogram (kg) and (BMI) within the range 18.5 to 32.0 kilogram per meter square (kg/m2) (inclusive) at Screening.
  • Male and female participants must follow protocol-specified guidance.
  • Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies

    • Is a woman of nonchildbearing potential (WONCBP)
    • Is a Woman of (WOCBP) and using a contraceptive method that is highly effective
    • A WOCBP must have a negative highly sensitive serum pregnancy test within 24 hours before the first dose of study intervention (i.e., Day -1 of each treatment period)
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Must be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, biliary (including gallstones or previous cholecystectomy), endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Have a history of malignant neoplasm (excepting definitively treated non melanoma skin cancer or carcinoma in situ of the uterine cervix, which may be enrolled at any time) within the last 5 years.
  • Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing.
  • Participation in the clinical study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 3 months.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrolment or past participation in another clinical study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within the last 30 days or 5.5 half-lives before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
  • Current enrolment or past participation in this clinical study.
  • Positive pre-study drug/alcohol screen, including tetrahydrocannabinol.
  • Positive (HIV) antibody test.
  • Positive coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) polymerase chain reaction test at check-in.
  • Presence of surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.
  • Positive virus (HCV) antibody test result at screening or within 3 months prior to starting study intervention.
  • Total >1.5x (ULN), including participants with Gilbert's syndrome.
  • Regular alcohol consumption within 6 months prior to the clinical study defined as: For sites in United States of America (USA), an average weekly intake of 3 units for males or 1.5 units for females.
  • History of known drugs of abuse, including tetrahydrocannabinol, in last 5 years.
  • Sensitivity to heparin or heparin-induced thrombocytopenia.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the clinical study.
  • Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.), within past 30 days prior to signing the consent and during the study.
  • Any dietary restrictions that would prevent the participant from consuming the site menu/meals.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Sequence 1

    In sequence 1, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 under fasting condition (Treatment A), followed by single dose of GSK5464714 in fed condition (Treatment B). There will be a washout period of minimum 7 days between each period.

    Drug: GSK5464714- Camlipixant

  • Experimental
    Sequence 2

    In sequence 2, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 in fed condition (Treatment B), followed by single dose of GSK5464714 under fasting condition (Treatment A). There will be a washout period of minimum 7 days between each period.

    Drug: GSK5464714- Camlipixant

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) from Time Zero to Infinity Post-Dose [AUC(0-inf)

    Time frame: Up to Day 3 for each period

  2. Maximum Observed Plasma Drug Concentration (Cmax)

    Time frame: Up to Day 3 for each period

Secondary outcomes

  1. Time to Maximum Observed Plasma Drug Concentration (Tmax)

    Time frame: Up to Day 3 for each period

  2. Apparent Terminal Phase Half-Life (t½)

    Time frame: Up to Day 3 for each period

  3. Apparent Oral Clearance (CL/F)

    Time frame: Up to Day 3 for each period

  4. AUC from Time Zero to Last Quantifiable Concentration [AUC(0-t)

    Time frame: Up to Day 3 for each period

  5. Apparent Volume of Distribution (Vz/F)

    Time frame: Up to Day 3 for each period

  6. Number of Participants Reported for Adverse events, Serious Adverse Events and Adverse Events of Special Interest

    Time frame: Up to 3 weeks

  7. Absolute Values for Clinical Laboratory Parameters Over Time

    Time frame: Up to 3 weeks

  8. Absolute Values for 12- Lead Electrocardiogram (ECG) Over Time

    Time frame: Up to 3 weeks

  9. Absolute Values for Vital Sign Measurements Over Time

    Time frame: Up to 3 weeks

  10. Changes from Baseline for Clinical Laboratory Parameters Over Time

    Time frame: Up to 3 weeks

  11. Changes from Baseline for 12- Lead ECG Over Time

    Time frame: Up to 3 weeks

  12. Changes from Baseline for Vital Sign Measurements Over Time

    Time frame: Up to 3 weeks

07

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2024, 1 month.

Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 11, 2024
StartActual
Jul 9, 2024
Primary completionActual
Aug 22, 2024
CompletionActual
Aug 26, 2024
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06497517
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Jul 9, 2024
Primary completion
Aug 22, 2024
Completion
Aug 26, 2024
Last update
Feb 7, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion